Crestline Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Crestline Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-14,120	Closed	-$494K	–	245
2018 Q2	$494K	Buy	14,120 +4,059	+40%	+$156K	0.05%	224
2018 Q1	$468K	Buy	+10,061	New	+$368K	0.06%	196
2017 Q3	–	Sell	-21,990	Closed	-$1.25M	–	182
2017 Q2	$1.25M	Buy	21,990 +7,770	+55%	+$390K	0.17%	68
2017 Q1	$764K	Buy	+14,220	New	+$803K	0.14%	68

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Crestline Management's KDNY Position: Q3 2018 in Review

Crestline Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2018, closing a stake of 14,120 shares — an estimated $494K sold.

Crestline Management first reported a position in KDNY in Q1 2017 and held it in 4 quarters. The position peaked at $1.25M in Q2 2017. 87 funds tracked by Wall St. Rank hold KDNY as of Q3 2018.

Crestline Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Crestline Management sold 14,120 Chinook Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $494K.
Crestline Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Crestline Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.25M in Q2 2017.
87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.